Study guide

3.4 Opioids, Opioid Toxidrome, and Naloxone Titration

Certified Specialist in Poison Information CSPI

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pharmacology & Toxicology Principles

1.1 Toxicokinetics: Absorption, Distribution, Metabolism, and Elimination Alterations in Overdose 1.2 Toxicodynamics, Receptor Pharmacology, and Dose-Response Relationships 1.3 Cellular and Biochemical Mechanisms of Toxicity 1.4 Hepatic Biotransformation, Phase I/II Reactions, and CYP450 Interactions

2 Chapter 2: Poison Center Case Assessment Fundamentals

2.1 Exposure History: The Questions That Change Management 2.2 Toxicologic Calculations: Doses, Concentrations, and Conversions

3 Chapter 3: Analgesics, Opioids & Over-the-Counter Medications

3.1 Acetaminophen Overdose: Pathophysiology, Rumack-Matthew Nomogram, and NAC Protocols 3.2 Salicylates: Pathophysiology, Acid-Base Derangements, and Urinary Alkalinization 3.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Miscellaneous OTC Analgesics 3.4 Opioids, Opioid Toxidrome, and Naloxone Titration 3.5 Cough and Cold Products, Antihistamines, Muscle Relaxants, and Local Anesthetics

4 Chapter 4: Psychotropic & Neurologic Medications

4.1 Tricyclic and Cyclic Antidepressants: Cardiotoxicity, ECG Findings, and Bicarbonate Therapy 4.2 SSRIs, SNRIs, Novel Antidepressants, and Serotonin Syndrome 4.3 Antipsychotics, Neuroleptic Malignant Syndrome, and Lithium Neurotoxicity 4.4 Benzodiazepines, Z-drugs, Barbiturates, and Major Anticonvulsants

5 Chapter 5: Cardiovascular Drugs & Substances of Abuse

5.1 Beta-Blockers, Calcium Channel Blockers, and High-Dose Insulin Euglycemia Therapy 5.2 Digoxin and Cardiac Glycosides: Mechanism, Arrhythmias, and Digoxin Immune Fab 5.3 Sympathomimetics, Cocaine, Amphetamines, Synthetic Cannabinoids, and Hallucinogens 5.4 Caffeine, Theophylline, and Over-the-Counter Stimulants 5.5 Cannabis, GHB, Nitrites, and Nicotine Products

6 Chapter 6: Endocrine, Antimicrobial & Miscellaneous Medications

6.1 Antidiabetic Agents, Metformin Lactic Acidosis, and Thyroid Hormone 6.2 Antimicrobials, Vitamins and Minerals, and Veterinary Products

7 Chapter 7: Household, Chemical & Inhalational Toxins

7.1 Caustic and Corrosive Ingestions: Acids vs. Alkalis, Tissue Necrosis, and Endoscopic Grading 7.2 Cleaning Products, Personal Care Products, and Household Chemicals 7.3 Hydrocarbons and Halogenated Solvents: Aspiration Risks and Myocardial Sensitization 7.4 Carbon Monoxide, Cyanide, Hydrogen Sulfide, and Inhalational Irritants

8 Chapter 8: Pesticides, Heavy Metals & Toxic Alcohols

8.1 Organophosphates, Carbamates, Pyrethroids, and Cholinesterase Antidotes 8.2 Rodenticides, Herbicides, Repellents, and Other Pesticides 8.3 Ethylene Glycol, Methanol, and Isopropanol: Metabolism, Osmolal Gaps, and Fomepizole 8.4 Lead, Mercury, Arsenic, Iron Toxicity, and Chelation Protocols

9 Chapter 9: Toxic Plants, Mushrooms & Foodborne Toxins

9.1 Toxic Plants: Cardiac Glycosides, Anticholinergics, Nicotinics, and Sodium Channel Activators 9.2 Oxalate, Irritant, Hallucinogenic, and Stimulant Plants 9.3 Mushroom Poisoning: Amatoxins, Monomethylhydrazine, Muscarine, and Coprine 9.4 Scombroid, Ciguatera, Tetrodotoxin, Paralytic Shellfish, and Botulism 9.5 Bacterial Foodborne Illness and Food Poisoning Triage

10 Chapter 10: Envenomations & Bites

10.1 North American Pit Vipers (Crotalinae): Envenomation Assessment and Antivenom Management 10.2 Elapid Snakebites (Coral Snakes): Neurotoxicity, Clinical Course, and Antivenin 10.3 Black Widow, Brown Recluse Spiders, and Bark Scorpion Stings 10.4 Hymenoptera Stings, Ticks, and Other Arthropods 10.5 Marine Envenomations: Jellyfish, Stingrays, Catfish, and Lionfish

11 Chapter 11: Clinical Assessment, Toxidromes & Triage

11.1 Recognition of Classic Toxidromes and Vital Sign Pattern Analysis 11.2 Severity Assessment, Exposure Urgency, and Poison Center Telephone Triage Flow 11.3 Home Observation vs. Emergency Department Referral Decision-Making 11.4 Diagnostic Toxicology: Acid-Base Analysis, Gaps, ECG Intervals, and Drug Testing

12 Chapter 12: Decontamination, Antidotes & Elimination

12.1 Gastrointestinal Decontamination: Activated Charcoal, Whole Bowel Irrigation, and Contraindications 12.2 Essential Poison Center Antidotes: Indications, Mechanisms, and Titration Pearls 12.3 Enhanced Elimination: Urinary Alkalinization, MDAC, Hemodialysis, and Hemoperfusion 12.4 Resuscitation and Supportive Care: Seizures, Hyperthermia, and Hemodynamic Shock

13 Chapter 13: Pediatric Poisoning & High-Risk Hazards

13.1 Pediatric "One-Pill-Can-Kill" Agents and Pediatric Toxic Dose Thresholds 13.2 Button Batteries, Rare-Earth Magnets, and Expandable Foreign Bodies 13.3 Developmental Ingestion Patterns, Liquid Detergent Pods, and Essential Oils

14 Chapter 14: Communication, NPDS Documentation & Prevention

14.1 Emergency Call Communication, Panicked Callers, and Healthcare Provider Consultations 14.2 National Poison Data System (NPDS) Coding Standards and Medical Outcome Categorization 14.3 Scheduled Follow-up Protocols, Medical Toxicologist Consultation Triggers, and Public Health Surveillance 14.4 Evidence-Based Poison Prevention, PPPA Regulations, and Community Outreach

3.4 Opioids, Opioid Toxidrome, and Naloxone Titration

Key Takeaways Explain This Topic AI

The opioid toxidrome is respiratory depression plus central nervous system depression plus miosis, and the respiratory rate and tidal volume, not the pupils, define severity.

Naloxone is titrated to adequate spontaneous ventilation rather than full alertness, starting at 0.04 to 0.4 mg intravenously in a dependent adult and 0.1 mg/kg in a child, because abrupt reversal causes agitation, vomiting, and pulmonary edema.

Naloxone lasts 30 to 90 minutes while methadone, buprenorphine, extended-release oxycodone, and many fentanyl analogues last far longer, so re-sedation is expected and an infusion set near two-thirds of the effective waking dose per hour is used.

Agent-specific hazards include methadone QT prolongation and torsades, tramadol and meperidine seizures, loperamide cardiac conduction and QT effects at abuse doses, diphenhydramine-like anticholinergic findings with diphenoxylate-atropine, and delayed apnea in toddlers exposed to buprenorphine films or discarded fentanyl patches.

A negative routine opiate immunoassay never excludes fentanyl, methadone, buprenorphine, tramadol, or a novel synthetic opioid, because the assay is calibrated to morphine.

Last updated: September 2026

Opioids bind mu, kappa, and delta receptors coupled to inhibitory G proteins. Activation closes voltage-gated calcium channels presynaptically, opens potassium channels postsynaptically, and reduces cyclic adenosine monophosphate, which together suppress neurotransmitter release. The clinically decisive effect is at the brainstem, where mu agonism blunts the medullary response to rising carbon dioxide and, at higher doses, abolishes the hypoxic drive.

The Cardinal Triad and Its Exceptions

Triad: central nervous system depression, respiratory depression (rate below about 10 to 12 breaths per minute or shallow tidal volume), and miosis.

Additional expected findings are bradycardia, hypotension, hypothermia, decreased bowel sounds, and non-cardiogenic pulmonary edema with high-potency or injected opioids.

Exception Explanation

Normal or dilated pupils Meperidine (normeperidine), propoxyphene, tramadol, severe hypoxia or acidosis, co-ingested sympathomimetic or antimuscarinic

  • Seizures Tramadol, meperidine, propoxyphene; also hypoxia from any opioid
  • Wide QRS Propoxyphene, loperamide at abuse doses
  • Prolonged QT with torsades Methadone, loperamide
  • Agitation rather than sedation Withdrawal after naloxone, or a stimulant co-ingestant
  • Anticholinergic signs in a child Diphenoxylate-atropine (Lomotil)

Clinical anchor: the respiratory rate is the vital sign that kills. A patient with pinpoint pupils breathing 16 times a minute needs observation; a patient breathing 6 times a minute needs ventilation and naloxone now.

Agent-Specific Hazards

Opioid Distinguishing Feature Practical Consequence

Methadone Half-life 15 to 60 hours; blocks the delayed rectifier potassium current Very prolonged apnea risk, QT prolongation and torsades; admit and monitor for 24 hours or more

Buprenorphine Partial mu agonist with high receptor affinity and a ceiling on respiratory depression in adults Relatively safe in tolerant adults, but films and tablets cause delayed, prolonged respiratory depression in toddlers ; reversal may need larger naloxone doses

Fentanyl and analogues High potency, rapid onset, lipophilic; carfentanil and nitazenes are far more potent Chest wall rigidity, rapid arrest, and repeat naloxone dosing; patches (including discarded ones) are a pediatric hazard

Tramadol Weak mu agonist plus serotonin and norepinephrine reuptake inhibition Seizures at therapeutic and overdose levels, serotonin toxicity, only partially naloxone-responsive

Meperidine Metabolite normeperidine accumulates, especially in kidney failure Tremor, myoclonus, seizures; naloxone does not reverse normeperidine neuroexcitation

Loperamide Peripherally restricted at label doses; abused at doses of hundreds of milligrams a day to self-treat withdrawal Wide QRS, marked QT prolongation, torsades, cardiac arrest; treat with sodium bicarbonate, magnesium, and overdrive pacing as needed

Diphenoxylate-atropine Two toxins in one tablet Early anticholinergic phase, then delayed (up to 12 to 24 hours) opioid apnea in children

Codeine and hydrocodone Require CYP2D6 activation Ultra-rapid metabolizers, including nursing mothers, generate high morphine concentrations

Kratom (mitragynine) Botanical partial mu agonist with stimulant effects at low dose Seizures, tachycardia, and opioid features in large exposures; often combined with other drugs

Naloxone: Titration, Not Reversal

Naloxone is a competitive antagonist at mu, kappa, and delta receptors with no intrinsic agonist activity. The therapeutic target is restoration of adequate spontaneous ventilation , not wakefulness.

Dosing Strategy

Situation Initial Dose Rationale

Adult with suspected dependence, spontaneous pulse 0.04 to 0.4 mg IV, doubled every 2 to 3 minutes Avoids precipitated withdrawal while restoring breathing

Opioid-naive adult with respiratory arrest 0.4 to 2 mg IV Rapid restoration is the priority

Cardiac arrest or profound hypoxia 2 mg IV, repeat as needed High-potency analogues may need cumulative doses well above 2 mg

  • Child 0.1 mg/kg IV, IM, or intranasal (maximum about 2 mg per dose) Children are rarely tolerant
  • No intravenous access Intramuscular or intranasal Onset delayed a few minutes; support ventilation meanwhile
  • Infusion Arithmetic

When re-sedation is expected, start an hourly infusion at about two-thirds of the total dose that restored ventilation , then titrate.

Example: 2 mg total was required. Infusion = about 1.3 mg per hour, adjusted to keep respirations adequate without withdrawal.

Consequences of Over-Reversal

Abrupt full reversal in a dependent patient produces catecholamine release with vomiting and aspiration risk, severe agitation, hypertension and tachycardia, and occasionally non-cardiogenic pulmonary edema. In a patient with pain or recent surgery it also unmasks severe pain and can precipitate withdrawal seizures in a neonate.

  • What Naloxone Does Not Fix
  • Tramadol and meperidine neuroexcitation
  • Xylazine sedation and bradycardia in an adulterated fentanyl exposure
  • Hypoxic brain injury already sustained
  • Aspiration pneumonitis or rhabdomyolysis from a prolonged down time

Airway first. Bag-valve-mask ventilation with oxygen corrects hypoxia while naloxone is drawn up, and it prevents the arrest that naloxone alone will not reverse.

Pediatric Single-Dose Lethality

One tablet, film, patch, or teaspoon can be fatal in a toddler. The highest-risk products are methadone solution, buprenorphine film, extended-release oxycodone or morphine, fentanyl patches (including used patches retrieved from a trash can), and diphenoxylate-atropine. Any credible exposure requires emergency evaluation and a monitored observation period, commonly 24 hours for methadone, buprenorphine, extended-release products, and diphenoxylate-atropine.

Testing and Counseling Pitfalls

Urine immunoassays are calibrated to morphine. Fentanyl, methadone, buprenorphine, tramadol, and novel synthetic opioids are missed. A negative screen in a patient who woke up with naloxone means the assay failed, not that the patient is opioid-free.

Dedicated fentanyl assays exist but do not detect all analogues.

Take-home naloxone counseling should cover recognizing slow or absent breathing, giving intranasal or intramuscular naloxone, calling 911 because the effect will wear off, staying with the person, and repeating the dose if breathing does not improve in 2 to 3 minutes.

Poison Center Case: Recurrent Apnea After a "Good Response"

A 34-year-old is found unresponsive with a respiratory rate of 4 and pinpoint pupils. Paramedics give 2 mg intranasal naloxone and the patient wakes, refuses transport, and is convinced by family to come in. Ninety minutes later he is again apneic.

Specialist actions. The CSPI explains that naloxone's 30 to 90 minute duration is shorter than the effect of most opioids, especially methadone, extended-release products, and potent analogues, so re-sedation is expected rather than surprising. The team ventilates, gives a small repeat bolus titrated to breathing, and starts an infusion at roughly two-thirds of the effective dose per hour. Because the patient responded to naloxone but the urine opiate screen is negative, the specialist notes that a synthetic opioid such as fentanyl is the likely agent and warns that xylazine adulteration can leave the patient sedated and bradycardic despite adequate reversal of the opioid component.